Advanced search
Publication Cover
Acta Oncologica Volume 49, 2010 - Issue 1
Journal homepage
1,241
Views
12
CrossRef citations to date
0
Altmetric
REVIEW ARTICLE

Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management

Pascal Wolter Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Herestraat 49, B-3000 Leuven, BelgiumCorrespondence[email protected]
&
Patrick Schöffski Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Herestraat 49, B-3000 Leuven, Belgium
Pages 13-23 | Received 19 Jun 2009, Accepted 25 Aug 2009, Published online: 10 Nov 2009

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Suvankar Banerjee, Shristi Kejriwal, Balaram Ghosh, Goverdhan Lanka, Tarun Jha & Nilanjan Adhikari. (2023) Fragment-based investigation of thiourea derivatives as VEGFR-2 inhibitors: a cross-validated approach of ligand-based and structure-based molecular modeling studies. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-17.
Read now
Amy Potter Pilotte. (2015) Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib. Current Medical Research and Opinion 31:7, pages 1363-1376.
Read now

Articles from other publishers (10)

Wanting Huang, Juan Li, Feng Qiu, Xingye Wu, Jun Zhang, Xuemei Li, Gaoqiong Yao & Shenyin Zhu. (2020) Therapeutic drug monitoring‐based dose optimization for imatinib‐associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: A case report. Journal of Clinical Pharmacy and Therapeutics 45:4, pages 856-862.
Crossref
H-B Qiu, W Zhuang, T Wu, S Xin, C-Z Lin, H-L Ruan, X Zhu, M Huang, J-L Li, X-Y Hou, Z-W Zhou & X-D Wang. (2017) Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. The Pharmacogenomics Journal 18:3, pages 460-466.
Crossref
Sharon Ovnat Tamir, Dafna Gershnabel Milk, Yehudah Roth, Udi Cinamon, Asher Winder, Ronen Brenner, Ariel Katz & Tal Marom. (2016) Laryngeal Side Effects of Tyrosine Kinase Inhibitors. Journal of Voice 30:5, pages 606-610.
Crossref
Liesbeth Cornelissen, Filip Claus, Pascal Wolter, Herlinde Dumez, Frederik De Keyzer, Evelyne Lerut, Hendrik Van Poppel & Benoit Beuselinck. (2014) Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib. European Radiology 25:2, pages 375-379.
Crossref
Samantha C. Sodergren, Alice White, Fabio Efficace, Mirjam Sprangers, Deborah Fitzsimmons, Andrew Bottomley & Colin D. Johnson. (2014) Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group. Critical Reviews in Oncology/Hematology 91:1, pages 35-46.
Crossref
J. J. Koldenhof, P. O. Witteveen, R. de Vos, M. Walraven, C. N. Tillier, H. M. W. Verheul & S. C. C. M. Teunissen. (2014) Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions. Supportive Care in Cancer.
Crossref
A Wegner & R Khoramnia. (2011) Neurosensory retinal detachment due to sunitinib treatment. Eye 25:11, pages 1517-1518.
Crossref
Jun-Eul Hwang, Ju-Young Yoon, Woo-Kyun Bae, Hyun-Jeong Shim, Sang-Hee Cho & Ik-Joo Chung. (2010) Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor. BMC Cancer 10:1.
Crossref
Christine A. Larsen, Roderick H. Dashwood & William H. Bisson. (2010) Tea catechins as inhibitors of receptor tyrosine kinases: Mechanistic insights and human relevance. Pharmacological Research 62:6, pages 457-464.
Crossref
Giorgio Scagliotti & Ramaswamy Govindan. (2010) Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer. The Oncologist 15:5, pages 436-446.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.